SKIV2L2 Inhibitors
Chemical inhibitors of SKIV2L2 can exert their inhibitory effects through a variety of cellular mechanisms, primarily by interfering with processes that are crucial for the cellular functions where SKIV2L2 is involved. Paclitaxel, for example, stabilizes microtubules and inhibits their disassembly, which is a vital process for cell division. Given that SKIV2L2 plays a role in RNA surveillance during mitosis, the presence of paclitaxel can indirectly inhibit the function of SKIV2L2 by disrupting the normal progression of cell division where SKIV2L2 activity is required. Similarly, compounds such as camptothecin and etoposide target DNA topoisomerases I and II, respectively. These topoisomerases are essential for DNA replication and transcription. By inhibiting these enzymes, camptothecin and etoposide can cause DNA damage and halt the cell cycle, indirectly reducing SKIV2L2's ability to process RNA because of the reduced demand for its activity in a compromised cell cycle.
Furthermore, mitoxantrone, another DNA intercalating agent that inhibits topoisomerase II, can lead to DNA breaks and cell cycle arrest, which would consequently limit the functional role of SKIV2L2 in the dividing cells. Bortezomib and MG-132 are proteasome inhibitors that prevent the degradation of misfolded proteins, leading to cell cycle arrest and apoptosis. The resulting disruption of cellular homeostasis can indirectly inhibit the function of SKIV2L2, which is closely related to RNA metabolism and the cell cycle. Actinomycin D and α-Amanitin exert their effect by inhibiting RNA polymerases, thereby drastically reducing RNA synthesis. The reduction in RNA synthesis can indirectly inhibit SKIV2L2 by decreasing the pool of RNA substrates that require processing and degradation, which are part of SKIV2L2's primary functions. Lastly, chemicals like cycloheximide, puromycin, and anisomycin inhibit protein synthesis at various stages. This inhibition can lead to a reduction in cellular processes dependent on new protein synthesis, among which those involving SKIV2L2 are included. By disrupting protein synthesis, these chemicals indirectly affect SKIV2L2's role in RNA processing and turnover, as the protein's function is tightly linked to the overall state of cellular homeostasis and protein synthesis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and thereby inhibits their disassembly, which is essential for cell division. SKIV2L2 is implicated in RNA surveillance and the resolution of RNA during mitosis; stabilization of microtubules can lead to the inhibition of cell division and indirectly inhibit SKIV2L2 function in rapidly dividing cells. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, which is necessary for DNA replication and transcription. By inhibiting topoisomerase I, camptothecin can lead to DNA damage and interfere with the cell cycle, potentially inhibiting the function of SKIV2L2 in processes that rely on DNA integrity and cell division. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits DNA topoisomerase II, which, like topoisomerase I, is integral to DNA replication and transcription. Inhibition of this enzyme can result in DNA strand breaks and halt cell division, which may indirectly inhibit SKIV2L2 activity in dividing cells. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA breaks and cell cycle arrest. As SKIV2L2 is involved in RNA processing during cell division, its function can be indirectly inhibited by the prevention of cell cycle progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can cause the accumulation of misfolded proteins, leading to cell cycle arrest and apoptosis. This can indirectly inhibit SKIV2L2 by disrupting cellular processes in which it is involved, particularly those related to RNA metabolism and cell cycle. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises endosomal pH and can disrupt endosome-mediated processes. Since SKIV2L2 is involved in the turnover of RNA-protein complexes, disruption of endosomal pathways could indirectly inhibit the protein's function in RNA surveillance. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to accumulation of proteins destined for degradation, potentially causing cell cycle arrest. By interfering with cellular proteostasis, MG-132 can indirectly inhibit SKIV2L2 function related to RNA processing and turnover. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and inhibits RNA polymerase, leading to inhibition of RNA synthesis. Though SKIV2L2 is not directly involved in transcription, inhibiting RNA synthesis can indirectly inhibit SKIV2L2 by limiting substrate availability for RNA processing. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin is an inhibitor of RNA polymerase II, leading to the inhibition of mRNA synthesis. As SKIV2L2 is involved in the degradation and processing of mRNA, inhibiting mRNA synthesis indirectly limits the functional role of SKIV2L2. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein elongation. This can lead to reduced protein synthesis and indirectly inhibit SKIV2L2 activity by disrupting cellular processes that depend on new protein synthesis, including RNA processing. | ||||||